Eosinophilic airway inflammation and exacerbations of COPD: a randomised controlled trial

No abstract is available for this paper.

• Publication year

  2007

• Venue

  European Respiratory Journal

• Publication date

  2007-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1183/09031936.00146306PMID 17301099
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Exhaled nitric oxide: a predictor of steroid response.

  2005cited by this paper
• Alveolar nitric oxide in adults with asthma: evidence of distal lung inflammation in refractory asthma

  2005cited by this paper
• CHRONIC OBSTRUCTIVE PULMONARY DISEASE Sputum eosinophilia and the short term response to inhaled mometasone in chronic obstructive pulmonary disease

  2005cited by this paper
• [Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease].

  2004cited by this paper
• The nature of small-airway obstruction in chronic obstructive pulmonary disease.

  2004cited by this paper
• Disease severity and the effect of fluticasone propionate on chronic obstructive pulmonary disease exacerbations

  2003cited by this paper
• Guidelines for the management of chronic obstructive pulmonary disease.

  2002cited by this paper
• Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial.

  2002influential reference
• Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease

  2002cited by this paper
• A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease

  2002cited by this paper
• Chronic obstructive pulmonary disease.

  2002cited by this paper
• GOLD SCIENTIFIC COMMITTEE. GLOBAL STRATEGY FOR THE DIAGNOSIS, MANAGEMENT, AND PREVENTION OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE. NHLBI/WHO GLOBAL INITIATIVE FOR CHRONIC OBSTRUCTIVE LUNG DISEASE (COLD) WORKSHOP SUMMARY

  2001cited by this paper
• Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary.

  2001cited by this paper
• Induced sputum and other outcome measures in chronic obstructive pulmonary disease: safety and repeatability.

  2001cited by this paper
• Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response.

  2000cited by this paper
• Chronic obstructive pulmonary disease.

  2000cited by this paper
• Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial

  2000cited by this paper
• Oral corticosteroids for exacerbations of chronic obstructive pulmonary disease

  2000cited by this paper
• Sputum eosinophilia and short-term response to prednisolone in chronic obstructive pulmonary disease: a randomised controlled trial.

  2000influential reference
• Efficacy of salmeterol xinafoate in the treatment of COPD.

  1999cited by this paper
• Markers of nitric oxide metabolism in sputum and exhaled air are not increased in chronic obstructive pulmonary disease

  1999cited by this paper
• Non-eosinophilic corticosteroid unresponsive asthma.

  1999cited by this paper
• Asthma attacks with eosinophilia predict mortality from chronic obstructive pulmonary disease in a general population sample.

  1999cited by this paper
• Minimisation: the platinum standard for trials?

  1998cited by this paper
• Exhaled nitric oxide in chronic obstructive pulmonary disease.

  1998cited by this paper
• Multicentre randomised placebo-controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease. International COPD Study Group.

  1998influential reference
• Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease.

  1998cited by this paper
• The use of induced sputum to investigate airway inflammation.

  1997cited by this paper
• BTS guidelines for the management of chronic obstructive pulmonary disease. The COPD Guidelines Group of the Standards of Care Committee of the BTS.

  1997cited by this paper
• Airway eosinophilia in chronic bronchitis during exacerbations.

  1994cited by this paper
• A measure of quality of life for clinical trials in chronic lung disease.

  1987cited by this paper

• Sputum Eosinophils Predict Annual Remission of the Frequent Exacerbator Phenotype in COPD: A Prospective Cohort Study

  2026cites this paper
• Eosinophilic endotype as a predictor of NIV success in COPD exacerbation with acute respiratory failure

  2026cites this paper
• PDE4-Selective Inhibition in Chronic Obstructive Pulmonary Disease and Pulmonary Fibrosis: Different Agents or Different Targets?

  2025cites this paper
• Relationship of fractional exhaled nitric oxide with blood eosinophilia in characterizing type-2 airway inflammation in treatment-naïve patients with chronic obstructive pulmonary disease

  2025cites this paper
• Mepolizumab in Chronic Obstructive Pulmonary Disease (COPD): A new frontier in biologic therapy

  2025cites this paper
• Assessment of Small Airways Function in Eosinophilic Preserved Ratio Impaired Spirometry

  2025cites this paper
• Initial treatment of COPD with LABA-ICS or LABA-LAMA: real-world comparative effectiveness

  2025cites this paper
• Sputum quality affects assessment of airway microbiology in childhood asthma

  2025cites this paper
• Diagnosing Type 2 Inflammation in COPD: Comparison of Blood and Sputum Eosinophil Assessment in the University of California Los Angeles COPD Phenotyping Study.

  2025cites this paper
• Chronic obstructive pulmonary disease, biological agents and small molecules: where do we stand?

  2025cites this paper
• Mepolizumab for COPD with Eosinophilic Phenotype following Hospitalization.

  2025cites this paper
• Dupilumab Versus Mepolizumab for COPD: Evaluating Efficacy Outcomes Using Placebo-Adjusted Indirect Treatment Comparison.

  2025cites this paper
• Assessment of the clinical prognosis of patients with chronic obstructive pulmonary disease using combined blood and sputum eosinophil counts

  2025cites this paper
• Short term exacerbation risk and exhaled nitric oxide in COPD.

  2025cites this paper
• Eosinophils in chronic obstructive pulmonary disease

  2025cites this paper
• Phenotypes of Exacerbations in Chronic Obstructive Pulmonary Disease

  2025cites this paper
• Induced sputum: current progress and prospect

  2025cites this paper
• Clinical utilization of airway inflammatory biomarkers in the prediction and monitoring of clinical outcomes in patients with chronic obstructive pulmonary disease

  2024cites this paper
• Endotyping Chronic Respiratory Diseases: T2 Inflammation in the United Airways Model

  2024cites this paper
• Εosinophilic Chronic Obstructive Pulmonary Disease. What Do We Know So Far?

  2024cites this paper
• Integrating hot topics and implementation of treatable traits in asthma

  2024cites this paper
• Lack of Association between Inhaled Corticosteroid Use Based on the Exhaled Nitric Oxide and Acute Exacerbation of Chronic Obstructive Pulmonary Disease

  2024cites this paper
• Eosinophilic inflammation: a key player in COPD pathogenesis and progression

  2024cites this paper
• Asthma, COPD, the "asthma-COPD" syndrome and severe asthma - relatives or "incidental strangers"?

  2024cites this paper
• Targeted therapy as a new perspective in the treatment of COPD

  2024cites this paper
• Time-Updated Phenotypic Guidance of Corticosteroids and Antibiotics in COPD: Rationale, Perspective and a Proposed Method

  2023cites this paper
• Dupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil Counts.

  2023cites this paper
• Association between Galectin-13 Expression and Eosinophilic Airway Inflammation in Chronic Obstructive Pulmonary Disease

  2023cites this paper
• Treatable traits models of care

  2023influential citation
• Therapeutic Targets and Precision Medicine in COPD: Inflammation, Ion Channels, Both, or Neither?

  2023cites this paper
• Chinese Research Progress Of Blood Eosinophils As Biomarkers In Chronic Obstructive Pulmonary Disease

  2023cites this paper
• The clinical efficacy of type 2 monoclonal antibodies in eosinophil-associated chronic airway diseases: a meta-analysis

  2023cites this paper
• Rethinking Blood Eosinophils for Assessing Inhaled Corticosteroids Response in COPD

  2023cites this paper
• Anti-IL5/IL5R Treatment in COPD: Should We Target Oral Corticosteroid-Dependent Patients?

  2023cites this paper
• A four-part guide to lung immunology: Invasion, inflammation, immunity, and intervention

  2023cites this paper
• Lung microbiome and cytokine profiles in different disease states of COPD: a cohort study

  2023cites this paper
• Treatable Traits in Airway Disease: From Theory to Practice.

  2023cites this paper
• Inhaled corticosteroids with combination inhaled long-acting beta2-agonists and long-acting muscarinic antagonists for chronic obstructive pulmonary disease.

  2023cites this paper
• Is FeNOtyping in COPD the path to precision medicine?

  2023cites this paper
• Fractional Exhaled Nitric Oxide (FeNO) in Patients with Stable Chronic Obstructive Pulmonary Disease: Short-Term Variability and Potential Clinical Implications

  2022cites this paper
• Plasma Extracellular Vesicle miRNA Profiles Distinguish Chronic Obstructive Pulmonary Disease Exacerbations and Disease Severity

  2022cites this paper
• Plasma Extracellular Vesicle miRNA Profiles Distinguish Chronic Obstructive Pulmonary Disease Exacerbations and Disease Severity

  2022cites this paper
• Greek Guidelines for the Management of COPD, a Proposal of a Holistic Approach Based on the needs of the Greek Community

  2022cites this paper
• Chronic obstructive pulmonary disease and atherosclerosis: common mechanisms and novel therapeutics

  2022cites this paper
• Research Progress on Discontinuation of ICS with Triple Inhaled Drugs for Chronic Obstructive Pulmonary Disease

  2022cites this paper
• Neuromedin U promotes human type 2 immune responses

  2022cites this paper
• Asthma–chronic obstructive pulmonary disease overlap syndrome – a brief review

  2022cites this paper
• Blood Eosinophils and Exhaled Nitric Oxide: Surrogate Biomarkers of Airway Eosinophilia in Stable COPD and Exacerbation

  2022cites this paper
• Neutrophyl – Lymphocyte Ratio (NLR) and C-Reactive Protein (CRP) Levels in Stable and Exacerbated Chronic Obstructive Pulmonary Disease (COPD) Patients in Persahabatan Hospital Jakarta

  2022cites this paper
• Eosinophilic COPD

  2022cites this paper
• Genetic Associations and Architecture of Asthma-COPD Overlap

  2022cites this paper
• Chronic Obstructive Pulmonary Disease Patients With High Peripheral Blood Eosinophil Counts Have Better Predicted Improvement in 6MWD After Rehabilitation

  2022cites this paper
• Novel Immunomodulatory Therapies for Respiratory Pathologies

  2022cites this paper
• Effects of inhaled corticosteroids (ICS) on lung microbiota and local immune response in long-term treatment of chronic obstructive pulmonary disease (COPD): utility of titration and therapeutic index

  2022cites this paper
• Comprehensive Care Management in Conjunction with Sputum Cytometry-Guided Pharmacotherapy in a Post-Discharge Clinic for Patients with COPD

  2021influential citation
• Blood Eosinophils in Chronic Obstructive Pulmonary Disease: Is There Enough Evidence?

  2021cites this paper
• The use of treatable traits to address COPD complexity and heterogeneity and to inform the care

  2021cites this paper
• The Role of Blood Eosinophils in the Management of COPD: An Attempt to Answer the Important Clinical Questions

  2021cites this paper
• Fractional Exhaled Nitric Oxide Guided-Therapy in Chronic Obstructive Pulmonary Disease: A Stratified, Randomized, Controlled Trial.

  2021cites this paper
• Long‐term oxygen treatment need is less frequent in eosinophilic COPD patients

  2021cites this paper
• Biomarkers in Chronic Obstructive Pulmonary Disease: Emerging Roles of Eosinophils and Procalcitonin

  2021cites this paper
• Moving towards a Treatable Traits model of care for the management of obstructive airways diseases.

  2021cites this paper
• Asthma COPD overlap: Insights into cellular and molecular mechanisms.

  2021cites this paper
• The prognostic factors of in-hospital death among patients with pneumonic COPD acute exacerbation.

  2021cites this paper
• Pathophysiology of Bronchiectasis

  2021cites this paper
• Interleukin-13: A pivotal target against influenza-induced exacerbation of chronic lung diseases.

  2021cites this paper
• Unravelling the mechanisms driving multimorbidity in COPD to develop holistic approaches to patient-centred care

  2021cites this paper
• Eicosanoids and Eosinophilic Inflammation of Airways in Stable COPD

  2021cites this paper
• From DREAM to REALITI‐A and beyond: Mepolizumab for the treatment of eosinophil‐driven diseases

  2021cites this paper
• Targeted therapy in eosinophilic chronic obstructive pulmonary disease

  2021cites this paper
• Using Blood Eosinophil Count as a Biomarker to Guide Corticosteroid Treatment for Chronic Obstructive Pulmonary Disease

  2021cites this paper
• Blood eosinophils on hospital admission for COPD exacerbation do not predict the recurrence of moderate and severe relapses

  2021cites this paper
• Molecular markers of type 2 airway inflammation are similar between eosinophilic severe asthma and eosinophilic chronic obstructive pulmonary disease

  2021cites this paper
• Hemopexin: A Novel Anti-inflammatory Marker for Distinguishing COPD From Asthma

  2021cites this paper
• Eosinophilia and fractional exhaled nitric oxide levels in chronic obstructive lung disease

  2021cites this paper
• Use of biologics in the treatment of asthma, COPD, ACOS, and idiopathic pulmonary fibrosis

  2020cites this paper
• The Role of Electronic Noses in Phenotyping Patients with Chronic Obstructive Pulmonary Disease

  2020cites this paper
• Epidemiology and issues of NIV‐treated AECOPD patients with hypercapnic respiratory failure in Shanghai: A multicentre retrospective survey

  2020cites this paper
• Dual Bronchodilator in the Era of Triple Therapy

  2020cites this paper
• Genetic associations and architecture of asthma-chronic obstructive pulmonary disease overlap

  2020cites this paper
• Eosinophilic inflammation in COPD: from an inflammatory marker to a treatable trait

  2020cites this paper
• Sputum quantitative cytometry in patients with interstitial lung disease and chronic cough.

  2020cites this paper
• Association between blood eosinophils with exacerbation and patient-reported outcomes in chronic obstructive pulmonary disease patients in an endemic area for parasitic infections: a prospective study

  2020cites this paper
• The sputum microbiome associated with different sub-types of AECOPD in a Chinese cohort

  2020cites this paper
• Sputum Inflammometry to Manage Chronic Obstructive Pulmonary Disease Exacerbations: Beyond Guidelines

  2020cites this paper
• TREATABLE TRAITS THAT PREDICT HEALTH STATUS AND TREATMENT RESPONSE IN AIRWAY DISEASE.

  2020cites this paper
• Endo-phenotyping of COPD patients

  2020cites this paper
• Role of Type2 Inflammatory Biomarkers in Chronic Obstructive Pulmonary Disease

  2020cites this paper
• Anti-IL-5 therapies for chronic obstructive pulmonary disease.

  2020cites this paper
• Lung Disease Diagnostic Model Through IgG Sensitization to Microbial Extracellular Vesicles

  2020cites this paper
• Disease burden of eosinophilic airway disease: Comparing severe asthma, COPD and asthma–COPD overlap

  2020cites this paper
• Blood eosinophils and its relation to sputum inflammation and sputum bacterial load in patients with acute exacerbation of chronic obstructive pulmonary disease

  2020cites this paper
• To study of sputum cytology in COPD and bronchial asthma

  2020cites this paper
• Acute exacerbations of chronic obstructive pulmonary disease: in search of diagnostic biomarkers and treatable traits

  2020cites this paper
• Safety of Eosinophil-Depleting Therapy for Severe, Eosinophilic Asthma: Focus on Benralizumab

  2020cites this paper
• Eosinophils in COPD - current concepts and clinical implications.

  2020cites this paper
• Inhaled Corticosteroid Treatment in Chronic Obstructive Pulmonary Disease (COPD): Boon or Bane?

  2020cites this paper
• Eosinophilic cationic protein as a non-invasive marker of the nature of inflammatory response in patients with chronic obstructive pulmonary disease

  2020cites this paper
• Chronic Obstructive Pulmonary Disease: A palliative medicine review of the disease, its therapies and drug interactions.

  2020cites this paper
• Blood eosinophil count, a marker of inhaled corticosteroid effectiveness in preventing COPD exacerbations in post-hoc RCT and observational studies: systematic review and meta-analysis

  2020cites this paper